All News

Joseph Saseen, PharmD, breaks down how the new PREVENT ASCVD calculator improves on its predecessor and what the expanded LDL-C goal framework means for treatment decisions in pharmacy practice.

Pharmacists guide HR+ breast cancer CDK4/6 therapy, tackling interactions, costs, and toxicity monitoring, and applying new clinical trial insights.

From bispecifics to real-world evidence, Amy Seung previews the science, community, and advocacy opportunities defining this year's meeting.

Deucravacitinib, a selective TYK2 inhibitor, demonstrates efficacy comparable to biologics while offering meaningful improvements in symptoms and quality of life for patients with psoriatic arthritis.

Craig Beavers discusses how mavacamten's established long-term safety data strengthen shared decision-making conversations, and outlines best practices for multidisciplinary collaboration when implementing cardiac myosin inhibitor therapy in patients with obstructive hypertrophic cardiomyopathy (oHCM).

Case reports show that alternative agents, including phenytoin, have been successful in resolving digoxin-induced arrhythmias.

CDK4/6 inhibitor therapies must by tailored by comorbidities, interactions, cost, and coordinated labs with pharmacist expertise to support high-risk patients.

Nutrition coaching and pharmacist support boost medication adherence, tackle access barriers, and strengthen chronic disease routines.

Craig Beavers explains how mavacamten's REMS program and its clearly defined echo-based monitoring protocols create a unique opportunity for pharmacists to take an active role in managing patients with obstructive hypertrophic cardiomyopathy (oHCM).

This week's episode covers the court ruling halting RFK Jr.'s childhood vaccine schedule changes, the FDA's RSV vaccine approval for adults aged 18–49, pharmacist-led GLP-1 optimization strategies, and new gabapentin data in SUD treatment settings.

FDA approves nivolumab with AVD for stage III/IV classical Hodgkin lymphoma, boosting PFS and redefining first-line care.

Sharon Nachman, MD, equips pharmacists with clear, evidence-based talking points to address vaccine hesitancy and help parents navigate the confusion created by the legal battle over childhood immunization schedules.

Community pharmacists boost asthma control by improving adherence, inhaler technique, and access—cutting exacerbations and emergency department visits.

Learn why uACR screening flags early vascular damage linking chronic kidney disease and cardiovascular health.

Artificial intelligence is emerging as a vital tool for pharmacists in cardiovascular care—supporting clinical decisions, patient education, and adherence while maintaining guideline alignment.

The FDA approval of the Wegovy pill offers a new, effective GLP-1 option for weight management, with pharmacists playing a key role in patient counseling and adherence support.

The expanded indication is supported by findings from the phase 3 TRANSCEND clinical trial.

A timely pharmacist referral and collaborative care approach can set off a chain of positive lifestyle changes.

How pharmacists enter sports medicine, guide safe supplements, prevent doping risks, and join athlete care teams through the Sports Pharmacy Network.

The acquisition brings an autoinjector platform and a broad device portfolio into emmbecta's growing chronic care ecosystem.

FDA fast-tracks higher-dose weekly semaglutide, showing up to 20.7% weight loss.

Respiratory syncytial virus hits older adults hard and is often missed. Learn symptoms, testing, and how new vaccines and pharmacists help prevent severe illness.

In patients with diabetes, liver stiffness testing flags hidden MASLD fibrosis and sharply higher death risk.

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, breaks down the key distinctions between obstructive and nonobstructive hypertrophic cardiomyopathy (oHCM) and explains how cardiac myosin inhibitors target the underlying disease mechanism.

Evidence questions anemia plus thrombocytopenia prognosis in primary myelofibrosis, helping oncology pharmacists refine hematology risk stratification.